Oppenheimer Asset Management Inc. Invests $236,000 in GeneDx Holdings Corp. $WGS

Oppenheimer Asset Management Inc. bought a new stake in GeneDx Holdings Corp. (NASDAQ:WGS) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 2,555 shares of the company’s stock, valued at approximately $236,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of WGS. GAMMA Investing LLC lifted its stake in shares of GeneDx by 151.7% in the 1st quarter. GAMMA Investing LLC now owns 438 shares of the company’s stock valued at $39,000 after acquiring an additional 264 shares during the last quarter. KBC Group NV bought a new stake in shares of GeneDx in the 1st quarter valued at about $81,000. Teacher Retirement System of Texas bought a new stake in shares of GeneDx in the 1st quarter valued at about $264,000. Principal Financial Group Inc. lifted its stake in shares of GeneDx by 354.5% in the 1st quarter. Principal Financial Group Inc. now owns 71,584 shares of the company’s stock valued at $6,340,000 after acquiring an additional 55,833 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of GeneDx by 6.3% in the 1st quarter. Bank of New York Mellon Corp now owns 43,489 shares of the company’s stock valued at $3,852,000 after acquiring an additional 2,575 shares during the last quarter. Institutional investors own 61.72% of the company’s stock.

Insider Transactions at GeneDx

In other GeneDx news, Director Casdin Capital, Llc sold 500,000 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $120.90, for a total transaction of $60,450,000.00. Following the transaction, the director owned 3,007,164 shares in the company, valued at approximately $363,566,127.60. This represents a 14.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Katherine Stueland sold 10,501 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total value of $1,275,556.47. Following the transaction, the chief executive officer owned 14,578 shares in the company, valued at $1,770,789.66. This trade represents a 41.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 556,375 shares of company stock worth $67,569,247 over the last quarter. Insiders own 29.60% of the company’s stock.

GeneDx Stock Up 4.1%

Shares of NASDAQ WGS opened at $136.91 on Monday. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18. GeneDx Holdings Corp. has a 12 month low of $55.17 and a 12 month high of $146.00. The firm has a market capitalization of $3.93 billion, a PE ratio of 1,521.22 and a beta of 2.00. The firm has a fifty day simple moving average of $124.27 and a two-hundred day simple moving average of $98.99.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.21. GeneDx had a return on equity of 20.22% and a net margin of 0.52%.The firm had revenue of $116.74 million for the quarter, compared to the consensus estimate of $104.33 million. GeneDx has set its FY 2025 guidance at EPS. Equities analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Analysts Set New Price Targets

WGS has been the subject of a number of recent research reports. BTIG Research boosted their target price on GeneDx from $140.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Wall Street Zen lowered GeneDx from a “buy” rating to a “hold” rating in a research note on Saturday. Zacks Research lowered GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 2nd. Piper Sandler lifted their price objective on GeneDx from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, September 11th. Finally, Wells Fargo & Company boosted their target price on GeneDx from $78.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 30th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $124.22.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.